TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04857996
Drug: UBX1325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered a single 50 μL UBX1325 IVT injection
Study: NCT05407909
Drug: SYHX2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHX2001 tablets, oral
Study: NCT06498687
Drug: CYR-064
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline Nasal Spray
Study: NCT05007561
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral sugar pill
Study: NCT05046847
Drug: TQB3811
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3811 is a second-generation TrkA inhibitor.
Study: NCT05506176
Drug: SIM0417
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose of 750 mg SIM0417 with 100 mg ritonavir.
Study: NCT05506176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (tablet)
Study: NCT02213575
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
Study: NCT05880056
Drug: Nerkardou (5 mg) & (10 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
Study: NCT05531422
Drug: Inhaled fentanyl aerosol
Normalized name: fentanyl Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study: NCT05531422
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were randomized to 6 BTP episodes, in which 4 BTP episodes were treated with inhaled fentanyl aerosol (with a starting dose of 25 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×25 µg) and 2 BTP episodes with placebo(0 µg every 4 minutes until adequate pain alleviation. The maximum doses are 6×0µg) in a random sequence.
Study: NCT04551222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical tablets to probenecid
Study: NCT04947254
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given ADT
Study: NCT06022939
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT04856787
Drug: SHR-1701、 BP102 、XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2：Single Group~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study: NCT04856787
Drug: SHR-1701、 BP102 、XELOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 3：Randomized~Drug:SHR-1701 30mg/kg，IV ,every 3 week~Drug：BP102 7.5mg/kg，IV,every 3 week~Drug: Oxaliplatin 130mg/m2 ，IV,every 3 week~Drug:Capecitabine The total daily dose was 2000mg/m2, OR，Each cycle was administered for 2 consecutive weeks, followed by a week of rest, with a treatment cycle every 21 days
Study: NCT06201897
Drug: ACTH/Oral Steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection ACTH or Oral Steroids in children with West Syndrome
Study: NCT04813705
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
Study: NCT05702424
Drug: IGM-7354
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
Study: NCT05290194
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
Study: NCT05622175
Drug: F8IL10
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10
Study: NCT05843188
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folic acid derivative
Study: NCT05843188
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antineoplastic agent
Study: NCT05130814
Drug: zinc cream or hyaluronic acid sodium salt + metallic silver
Normalized name: formic acid, sodium salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied to prevent and/or treat the skin maceration of the surrounding area
Study: NCT06543303
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05835986
Drug: RO7507062
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7507062 solution for injection will be administered SC as specified in each treatment arm.
Study: NCT06561061
Drug: zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dispersible (20 mg) tablet
Study: NCT06561061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible tablet
Study: NCT04723147
Drug: Carbidopa Levodopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
Study: NCT04723147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
Study: NCT05119569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT04753437
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin tablets.
Study: NCT05242042
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Study: NCT05258773
Drug: SENS-401 (R-Azasetron Besylate)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
Study: NCT05641870
Drug: Chemoradiation treatment regimen and maintenance (if amenable)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
Study: NCT05699005
Drug: Packed Red Blood Cells (PRBCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.
Study: NCT05784779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once daily before bedtime (qhs)
Study: NCT06340048
Drug: HiCM-188 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
Study: NCT05418673
Drug: BIIB122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04819100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06253923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo for this study is 0.9% Sodium Chloride IV Solution.
Study: NCT04762953
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Leucovorin
Study: NCT04762953
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV 5-FU
Study: NCT06299111
Drug: REGN9933
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) single dose administered
Study: NCT06299111
Drug: REGN7508
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV single dose administered
Study: NCT06299111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV single dose administered
Study: NCT04777357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT04704505
Drug: Bipolar Androgen Therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
Study: NCT05613868
Drug: TPN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/ day up to 400mg/day of TPN-101
Study: NCT04542603
Drug: [11C]PiB and 18F-labeled DPA-714 PET scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
Study: NCT06052163
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
Study: NCT06052163
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo has no active properties and is taken orally.
Study: NCT05251181
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Study: NCT05761574
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Study: NCT05761574
Drug: Naproxen Sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen Sodium will be administered orally.
Study: NCT05761574
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen will be administered orally.
Study: NCT05761574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT05060705
Drug: Efesovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Study: NCT05472259
Drug: 5 FU
Normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Study: NCT05472259
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Study: NCT05122650
Drug: JZP385
Approvals — FDA: no, EMA: no, PMDA: no
Description: JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
Study: NCT05275205
Drug: UBX1325 injection 50 μL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
Study: NCT05275205
Drug: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
Study: NCT06433674
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
Study: NCT04272632
Drug: 4 ml/kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Study: NCT04272632
Drug: 8 ml/kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Study: NCT04272632
Drug: 12 ml/kg group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Study: NCT05194839
Drug: RIST4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Study: NCT05194839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05255094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study: NCT05255094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study: NCT06048146
Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
Study: NCT06048146
Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
Study: NCT05014334
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromy 500mg, twice daily for 14 days.
Study: NCT06390501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study: NCT04776525
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m2 over four hours day 1
Study: NCT04481919
Drug: Protocolized diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The urine sodium, urine creatinine and serum creatinine results will be input into the diuretic calculator and the diuretic dose will be chosen based on daily goals for urine output and net negative fluid balance.
Study: NCT04876755
Drug: MBM-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBM-02 is an HIF-1 and HIF-2 inhibitor.
Study: NCT05731258
Drug: Liposomal doxorubicin containing regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
Study: NCT06587737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo, lacking active ingredient, once-daily
Study: NCT05917288
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care will be administered
Study: NCT05738382
Drug: BG2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT04867252
Drug: Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
Study: NCT05423522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
Study: NCT05695313
Drug: OnLife®
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily
Study: NCT04840264
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Study: NCT06062914
Drug: oral nutritional supplements
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only ONS was used as enteral nutrition
Study: NCT06179303
Drug: Therapeutic Estradiol
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05164341
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04231084
Drug: Vasodilator testing (Inhaled Nitric Oxide)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Study: NCT04231084
Drug: Vasodilator testing (Inhaled Epoprostenol)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Study: NCT05326659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, applied twice daily for 12 weeks after enrolment.
Study: NCT05530447
Drug: Samelisant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT05649228
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Study: NCT06609356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * T1DM participants in the Hi-Ins study will receive an oral placebo. During the Eu-Ins study they will receive an SGLT2i.~* CGK-MODY participants and healthy volunteers will receive placebo in both studies.
Study: NCT04715152
Drug: ACB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
Study: NCT05566743
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance capecitabine after 4 months of FOLFRINOX
Study: NCT06558656
Drug: NTQ5082 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.
Study: NCT05222737
Drug: spirazole forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: adminstration of spirazole forte with a dose 17 mg per kg